JNJ vs LLY
Johnson & Johnson and Lilly (Eli), both Healthcare
Lilly (Eli) is the larger company at $980B against $550B. On trailing earnings JNJ is the cheaper of the two at a P/E of 31.2 against 37.7, a gap that is only a bargain if the two are growing at similar rates. Over the past year LLY returned +61% against +56% for JNJ.
| Figure | JNJ | LLY |
|---|---|---|
| Last close | $269 | $1124 |
| Market cap | $550B | $980B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 31.2 | 37.7 |
| Dividend yield | 1.9% | 0.6% |
| 1-year return | +56% | +61% |
| 5-year return | +78% | +337% |
| Ryufin Smart Scoresector-relative, 1–10 | 8/10 | 8/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Johnson & Johnson
Revenue of $25B in Q2 2026, net income $5.5B. Its largest reported line is DARZALEX, 19% of the disclosed total.
Lilly (Eli)
Revenue of $23B in Q2 2026, net income $7.1B. Its largest reported line is Cardiometabolic Health, 47% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.